Filament Health Logo
About Us
Technology
Why Natural?
Drug Development
Drug Access & Clinical Trials
Social Responsibility
Investors
News
Filament Logo
Sign up for our newsletter
I am interested in
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
About Us
Technology
Why Natural?
Drug Development
Drug Access & Clinical Trials
Social Responsibility
Investors
News
Twitter icon
LinkedIn icon
Instagram icon
YouTube icon
Privacy Policy

Recent News

Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval

Benzinga

November 8, 2021
News >
Recent News
>
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
Share this post:
Twitter icon
LinkedIn icon
Sign up for our newsletter
Visit:
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
Read the full article

read more News

Press Release

Filament Health Announces Authorization Of Phase 2 Clinical Trial Studying Botanical Psilocybin For Prolonged Grief Disorder

June 11, 2025
Press Release

Filament Health Announces Transition From OTCQB To OTC Pink Limited

May 27, 2025
Press Release

Filament Health Announces Voluntary Delisting From Cboe Canada

May 19, 2025

Sign up for our newsletter

I am interested in
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Sitemap
HomeAbout UsTechnologyWhy Natural?Drug DevelopmentDrug Access & Clinical TrialsInvestorsNews
Contact
210-4475 Wayburne Drive
Burnaby, BC  V5G 4X4
General InquiriesMedia InquiriesInvestor InquiriesCareers
Twitter icon
LinkedIn icon
Instagram icon
YouTube icon
Copyright © Filament Health. All rights reserved.
Privacy Policy